Towards improved process efficiency in vaccine innovation: The Vaccine Innovation Cycle as a validated, conceptual stage-gate model.

Abstract:

:Continuing investments in vaccine innovation are insufficiently translated into market entries of novel vaccines. This innovation paradox is in part caused by stakeholders lacking complete understanding of the complex array of steps necessary for vaccine development and collaboration difficulties between the wide variety of stakeholders involved. Models providing cross-domain understanding can improve collaboration but currently lack both comprehensibility and granularity to enable a prioritized view of activities and criteria. Key opinion leaders (KOLs) were asked to contribute to the definition of a vaccine innovation cycle (VIC). In a first step, 18 KOLs were interviewed on the stages (activities and results) and gates (evaluation criteria and outcomes) of vaccine innovation. This first description of the VIC was subsequently validated and refined through a survey among 46 additional KOLs. The VIC identifies 29 distinct stages and 28 corresponding gates, distributed in ten different but integrated workstreams, and comprehensibly depicted in a circular innovation model. Some stage-gates occur at defined moments, whereas the occurrence and timing of other stage-gates is contingent on a variety of contextual factors. Yet other stage-gates continuously monitor internal and external developments. A gap-overlap analysis of stage-gate criteria demonstrated that 5 out of 11 criteria employed by vaccine developers correspond with criteria employed by competent (regulatory) authorities. The VIC provides a comprehensive overview of stage-gates throughout the value chain of vaccine innovation. Its cyclical nature highlights the importance of synchronizing with unmet needs and market changes, and conceptualizes the difference between incremental and radical vaccine innovation. Knowledge on the gap between internal and external criteria will enhance the viability of newcomers to the field. The VIC can be used by stakeholders to improve understanding and communication in forming collaborative alliances and consortia. Such a boundary-spanning function may contribute to the reduction of process inefficiencies, especially in public-private partnerships.

journal_name

Vaccine

journal_title

Vaccine

authors

Van de Burgwal LHM,Ribeiro CDS,Van der Waal MB,Claassen E

doi

10.1016/j.vaccine.2018.10.061

subject

Has Abstract

pub_date

2018-11-26 00:00:00

pages

7496-7508

issue

49

eissn

0264-410X

issn

1873-2518

pii

S0264-410X(18)31429-4

journal_volume

36

pub_type

杂志文章

相关文献

VACCINE文献大全
  • Strategies for financial sustainability of immunization programs: a review of the strategies from 50 national immunization program financial sustainability plans.

    abstract::Financial sustainability plans (FSPs) were developed by over 50 of the world's poorest countries receiving funding support from the Global Alliance for Vaccines and Immunization (GAVI) to introduce new and underused vaccines, injection safety and immunization service support between 2000 and 2006. These plans were ana...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2008.10.014

    authors: Kamara L,Milstien JB,Patyna M,Lydon P,Levin A,Brenzel L

    更新日期:2008-12-02 00:00:00

  • Serine proteases of Leishmania amazonensis as immunomodulatory and disease-aggravating components of the crude LaAg vaccine.

    abstract::We previously demonstrated that intradermal and intramuscular vaccination with Leishmania amazonensis promastigote antigens (LaAg) increases the susceptibility of BALB/c mice to cutaneous leishmaniasis. In this study, we investigated the role played by serine and cysteine proteases as disease-promoting components of L...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.04.109

    authors: de Matos Guedes HL,Pinheiro RO,Chaves SP,De-Simone SG,Rossi-Bergmann B

    更新日期:2010-07-26 00:00:00

  • Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies.

    abstract::A HIV-1 tier system has been developed to categorize the various subtype viruses based on their sensitivity to vaccine-induced neutralizing antibodies (NAbs): tier 1 with greatest sensitivity, tier 2 being moderately sensitive, and tier 3 being the least sensitive to NAbs (Mascola et al., J Virol 2005; 79:10103-7). He...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.05.024

    authors: Coleman JK,Pu R,Martin MM,Noon-Song EN,Zwijnenberg R,Yamamoto JK

    更新日期:2014-02-03 00:00:00

  • Effective mucosal immunization against respiratory syncytial virus using purified F protein and a genetically detoxified cholera holotoxin, CT-E29H.

    abstract::We exploited the powerful adjuvant properties of cholera holotoxin (CT) to create a mucosally administered subunit vaccine against respiratory syncytial virus (RSV). A genetically detoxified mutant CT with an E to H substitution at amino acid 29 of the CT-A1 subunit (CT-E29H) was compared to wild type CT for toxicity ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(00)00058-x

    authors: Tebbey PW,Scheuer CA,Peek JA,Zhu D,LaPierre NA,Green BA,Phillips ED,Ibraghimov AR,Eldridge JH,Hancock GE

    更新日期:2000-06-01 00:00:00

  • Compatibility of a live infectious bovine rhinotraheitis (IBR) marker vaccine and an inactivated bovine viral diarrhoea virus (BVDV) vaccine.

    abstract::The target animals and vaccination regimes for vaccines against the bovine rhinotracheitis (IBR) and the bovine viral diarrhoea virus (BVDV) are very similar. Therefore, we have compared different schedules for the combined use of a live IBR marker vaccine and an inactivated BVD vaccine. The neutralizing antibody resp...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.06.050

    authors: Alvarez M,Bielsa JM,Santos L,Makoschey B

    更新日期:2007-09-04 00:00:00

  • Decline of varicella vaccination in German surveillance regions after recommendation of separate first-dose vaccination for varicella and measles-mumps-rubella.

    abstract:BACKGROUND:Germany introduced routine varicella (V) vaccination in 2004. Due to a slightly increased risk of febrile convulsions after first-dose application of combined measles-mumps-rubella-varicella (MMRV) vaccine separate first-dose vaccinations with MMR and monovalent V vaccine were recommended in September 2011. ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.12.065

    authors: Streng A,Liese JG

    更新日期:2014-02-12 00:00:00

  • Development of lactococcal GEM-based pneumococcal vaccines.

    abstract::We report the development of a novel protein-based nasal vaccine against Streptococcus pneumoniae, in which three pneumococcal proteins were displayed on the surface of a non-recombinant, killed Lactococcus lactis-derived delivery system, called Gram-positive Enhancer Matrix (GEM). The GEM particles induced the produc...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.09.026

    authors: Audouy SA,van Selm S,van Roosmalen ML,Post E,Kanninga R,Neef J,Estevão S,Nieuwenhuis EE,Adrian PV,Leenhouts K,Hermans PW

    更新日期:2007-03-22 00:00:00

  • Intranasal immunization with SIV virus-like particles (VLPs) elicits systemic and mucosal immunity.

    abstract::By using a baculovirus expression system, we have successfully produced simian immunodeficiency virus (SIV)-like particles (VLPs) with high levels of biologically active SIV envelope (Env) incorporated on their surfaces. To study whether SIV VLPs represent effective mucosal immunogens, we immunized groups of mice with...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(02)00160-3

    authors: Yao Q,Vuong V,Li M,Compans RW

    更新日期:2002-06-07 00:00:00

  • fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.

    abstract::Meningococci bind human fH to down-regulate complement, which enhances survival of the bacteria in serum. A major fH ligand is the vaccine candidate, factor H-binding protein (fHbp). Although fHbp has been considered an essential meningococcal virulence factor, rarely, invasive isolates with absent fHbp genes or frame...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2013.06.009

    authors: Giuntini S,Vu DM,Granoff DM

    更新日期:2013-08-28 00:00:00

  • Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

    abstract::Neisseria meningitidis, the causative agent of invasive meningococcal disease (IMD), is classified into different serogroups defined by their polysaccharide capsules. Meningococcal serogroups A, B, C, W, and Y are responsible for most IMD cases, with serogroup B (MenB) causing a substantial percentage of IMD cases in ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2020.08.031

    authors: Findlow J,Bayliss CD,Beernink PT,Borrow R,Liberator P,Balmer P

    更新日期:2020-11-17 00:00:00

  • Immunization of mice with DNA coding for the variable regions of anti-idiotypic antibody generates antigen-specific response.

    abstract::Understanding the mechanisms of generation and maintenance of immunological memory is crucial for rational vaccine design. A hypothesis known as relay hypothesis was earlier proposed which explains the maintenance of immunological memory through interaction of idiotypic and anti-idiotypic lymphocytes. In the present s...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.04.005

    authors: Vani J,Nayak R,Shaila MS

    更新日期:2007-06-21 00:00:00

  • The humoral immune response and protective efficacy of vaccination with inactivated split and whole influenza virus vaccines in BALB/c mice.

    abstract::Recently the urgency of developing a pandemic influenza vaccine has lead to the re-evaluation of the use of whole virus vaccine. We have compared the humoral immune response and the protective efficacy of whole and split influenza virus vaccines in mice. Whole virus vaccine was more immunogenic particularly after the ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2006.05.040

    authors: Cox RJ,Hovden AO,Brokstad KA,Szyszko E,Madhun AS,Haaheim LR

    更新日期:2006-11-10 00:00:00

  • ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

    abstract::Recently avian influenza A viruses of the H5N1 subtype were shown to infect humans in the Hong Kong area, resulting in the death of six people. Although these viruses did not efficiently spread amongst humans, these events illustrated that influenza viruses of subtypes not previously detected in humans could be at the...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(98)00390-9

    authors: Rimmelzwaan GF,Claas EC,van Amerongen G,de Jong JC,Osterhaus AD

    更新日期:1999-03-17 00:00:00

  • STING pathway stimulation results in a differentially activated innate immune phenotype associated with low nitric oxide and enhanced antibody titers in young and aged mice.

    abstract:BACKGROUND:One of the most concerning public health issues, related to vaccination and disease prevention, is the inability to induce durable immune responses following a single-dose immunization. In this regard, the nature of the inflammatory environment induced by vaccine adjuvants can negatively impact the resulting...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.04.004

    authors: Darling RJ,Senapati S,Kelly SM,Kohut ML,Narasimhan B,Wannemuehler MJ

    更新日期:2019-05-06 00:00:00

  • Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice.

    abstract::It has been known that influenza A virus infection induces a cross-protective immunity against infection by viruses with different subtypes of viral envelope proteins, hemagglutinin (HA) and neuraminidase (NA). This heterosubtypic immunity is generally mediated by cytotoxic T lymphocytes (CTL) reactive to specific epi...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/s0264-410x(03)00234-2

    authors: Takada A,Matsushita S,Ninomiya A,Kawaoka Y,Kida H

    更新日期:2003-07-04 00:00:00

  • Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus.

    abstract:OBJECTIVES:With the re-emergence of chikungunya virus (CHIKV) in an explosive form and in the absence of a commercially available vaccine, we aimed to develop candidate vaccines employing recombinant E2 protein or chemically inactivated whole virus. DESIGN AND METHODS:E2 gene of CHIKV isolate of ECSA genotype was clon...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.07.072

    authors: Kumar M,Sudeep AB,Arankalle VA

    更新日期:2012-09-21 00:00:00

  • Killed Bacillus subtilis spores as a mucosal adjuvant for an H5N1 vaccine.

    abstract::Heat killed spores of the Gram-positive bacterium Bacillus subtilis have been evaluated as a vaccine delivery system with mucosal adjuvant properties for influenza. Killed spores were able to bind H5N1 virions (NIBRG-14; clade 1) and, when intra-nasally administered to mice, resulting immune responses, both humoral an...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2012.03.016

    authors: Song M,Hong HA,Huang JM,Colenutt C,Khang DD,Nguyen TV,Park SM,Shim BS,Song HH,Cheon IS,Jang JE,Choi JA,Choi YK,Stadler K,Cutting SM

    更新日期:2012-05-09 00:00:00

  • Smallpox and its eradication in the Democratic Republic of Congo: lessons learned.

    abstract::Smallpox eradication is considered to be one of the most remarkable accomplishments of the 20th century. Lessons learned from the campaign during the 1960s and 1970s in the Democratic Republic of Congo (DRC) can provide important information for the development of other eradication programs including polio. The DRC is...

    journal_title:Vaccine

    pub_type: 历史文章,杂志文章,评审

    doi:10.1016/j.vaccine.2011.10.049

    authors: Muyembe-Tamfum JJ,Mulembakani P,Lekie RB,Szczeniowski M,Ježek Z,Doshi R,Hoff N,Rimoin AW

    更新日期:2011-12-30 00:00:00

  • Prior DNA vaccination does not interfere with the live-attenuated measles vaccine.

    abstract::The currently used live-attenuated measles vaccine is very effective although maternal antibody prevents its administration prior to 6 months of age. We are investigating the ability of a DNA vaccine encoding the measles viral hemagglutinin, fusion and nucleoprotein to protect newborn infants from measles. Here, we sh...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2003.08.020

    authors: Premenko-Lanier M,Rota P,Rhodes G,Bellini W,McChesney M

    更新日期:2004-01-26 00:00:00

  • Systematic review of reporting rates of adverse events following immunization: an international comparison of post-marketing surveillance programs with reference to China.

    abstract:BACKGROUND:China is the most populous country in the world, with an annual birth cohort of approximately 16 million, requiring an average of 500 million vaccine doses administered annually. In China, over 30 domestic and less than 10 overseas vaccine manufacturers supply over 60 licensed vaccine products, representing ...

    journal_title:Vaccine

    pub_type: 杂志文章,评审

    doi:10.1016/j.vaccine.2012.11.051

    authors: Guo B,Page A,Wang H,Taylor R,McIntyre P

    更新日期:2013-01-11 00:00:00

  • Poliovirus seroprevalence before and after interruption of poliovirus transmission in Kano State, Nigeria.

    abstract:INTRODUCTION:In September 2015, Nigeria was removed from the list of polio-endemic countries after more than 12months had passed since the detection of last wild poliovirus case in the country on 24 July 2014. We are presenting here a report of two polio seroprevalence surveys conducted in September 2013 and October 20...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.08.058

    authors: Iliyasu Z,Verma H,Craig KT,Nwaze E,Ahmad-Shehu A,Jibir BW,Gwarzo GD,Gajida AU,Weldon WC,Steven Oberste M,Takane M,Mkanda P,Muhammad AJG,Sutter RW

    更新日期:2016-09-30 00:00:00

  • Mapping financial flows for immunisation in Uganda 2009/10 and 2010/11: New insights for methodologies and policy.

    abstract:BACKGROUND:The Global Vaccine Action Plan highlights the need for immunisation programmes to have sustainable access to predictable funding. A good understanding of current and future funding needs, commitments, and gaps is required to enhance planning, improve resource allocation and mobilisation, and to avoid funding...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2014.12.053

    authors: Guthrie T,Zikusooka C,Kwesiga B,Abewe C,Lagony S,Schutte C,Marinda E,Humphreys K,Motlogelwa K,Nombewu ZC,Brenzel L,Kinghorn A

    更新日期:2015-05-07 00:00:00

  • Immune effects of the vaccine of live attenuated Aeromonas hydrophila screened by rifampicin on common carp (Cyprinus carpio L).

    abstract::Aeromonas hydrophila, as a strong Gram-negative bacterium, can infect a wide range of freshwater fish, including common carp Cyprinus carpio, and cause the huge economic loss. To create the effective vaccine is the best way to control the outbreak of the disease caused by A. hydrophila. In this study, a live attenuate...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2016.04.075

    authors: Jiang X,Zhang C,Zhao Y,Kong X,Pei C,Li L,Nie G,Li X

    更新日期:2016-06-08 00:00:00

  • Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.

    abstract::The repetitive structure of compact virus-like particles (VLPs) provides high density displays of antigenic sequences, which trigger key parts of the immune system. The hepatitis B virus (HBV) and human papilloma virus (HPV) vaccines exploit the assembly competence of structural proteins, which are the effective immun...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2019.01.056

    authors: Kingston NJ,Kurtovic L,Walsh R,Joe C,Lovrecz G,Locarnini S,Beeson JG,Netter HJ

    更新日期:2019-03-14 00:00:00

  • Measles vaccine adverse events reported in the mass vaccination campaign of Sichuan province, China from 2007 to 2008.

    abstract::The aim of this study was to characterize the adverse events of attenuated measles vaccine in mainland China. We carried out prospective follow-up of adverse events after mass measles immunization practices, categorizing them into two groups: allergic reactions and serious adverse events. The incidence of anaphylaxis ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2009.10.106

    authors: Shu M,Liu Q,Wang J,Ao R,Yang C,Fang G,Wan C,Guo W

    更新日期:2011-04-18 00:00:00

  • A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSV.

    abstract::Respiratory syncytial virus (RSV) is the most common cause of viral bronchiolitis and pneumonia in children. The present study compares the level of attenuation, genetic stability and efficacy of three conditional-lethal temperature-sensitive (ts) mutants of the RSV A2 wild-type virus, designated ts-1, ts-1-NG1, and t...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/0264-410x(93)90168-w

    authors: Crowe JE Jr,Collins PL,London WT,Chanock RM,Murphy BR

    更新日期:1993-11-01 00:00:00

  • A randomized, observer-blinded, equivalence trial comparing two variations of Euvichol®, a bivalent killed whole-cell oral cholera vaccine, in healthy adults and children in the Philippines.

    abstract:BACKGROUND:To contribute to the global demand for oral cholera vaccine (OCV), the production of Euvichol® was scaled up with elimination of thimerosal. To demonstrate the equivalence of the variations, a study was carried out in the Philippines. METHODS:Healthy male and female adults and children in Manila were random...

    journal_title:Vaccine

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.vaccine.2018.05.102

    authors: Russo P,Ligsay AD,Olveda R,Choi SK,Kim DR,Park JY,Park JY,Syed KA,Dey A,Kim YH,Lee SH,Kim J,Chon Y,Digilio L,Kim CW,Excler JL

    更新日期:2018-07-05 00:00:00

  • Th2-polarisation of cellular immune memory to neonatal pertussis vaccination.

    abstract::Current infant vaccination against pertussis in North America and Australia requires three doses of vaccines including diphtheria, tetanus and acellular pertussis antigens (DTaP) at 2, 4 and 6 months of age. Interest is growing in the possibility that vaccination at birth might provide earlier protection of infants, b...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2010.01.010

    authors: White OJ,Rowe J,Richmond P,Marshall H,McIntyre P,Wood N,Holt PG

    更新日期:2010-03-19 00:00:00

  • Targeting subcapsular antigens for prevention of Klebsiella pneumoniae infections.

    abstract::Vaccination strategies against Klebsiella pneumoniae have largely focussed on the polysaccharide capsule. However, the large number and high prevalence of individual capsular serotypes limits the widespread applicability of capsule-based vaccines. This study establishes that immunization with purified LPS can protect ...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2008.07.100

    authors: Clements A,Jenney AW,Farn JL,Brown LE,Deliyannis G,Hartland EL,Pearse MJ,Maloney MB,Wesselingh SL,Wijburg OL,Strugnell RA

    更新日期:2008-10-16 00:00:00

  • Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

    abstract::In this study, we compare four different adjuvants, LT(R192G), CpG ODN, MPL((R))TDM, and alum, for their ability to affect the magnitude, distribution, and duration of antibody responses against F1-V, the lead-candidate antigen for the next generation vaccine against plague, in a murine model. In addition, three diffe...

    journal_title:Vaccine

    pub_type: 杂志文章

    doi:10.1016/j.vaccine.2007.09.030

    authors: Uddowla S,Freytag LC,Clements JD

    更新日期:2007-11-19 00:00:00